Bank of New York Mellon Corp vs Tenet Healthcare Corporation — how do they compare? Bank of New York Mellon Corp trades at $159.23 (market cap $106.05B), while Tenet Healthcare Corporation trades at $188.05 (market cap $15.82B). The key difference: Bank of New York Mellon Corp is far larger — about 6.7× Tenet Healthcare Corporation's market cap, and Bank of New York Mellon Corp pays a 1.37% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| BNY | THC | |
|---|---|---|
Market Cap | $106.05B | $15.82B |
Sector | Financials | Health |
52-Week High | $154.50 | $244.80 |
52-Week Low | $95.16 | $148.38 |
Dividend Yield | 1.37% | — |
Enterprise Value | — | $26.06B |
Signals from Pluang's Aura AI — not financial advice
BNY trades at $151.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue growth has been steady, rising from $16.0B in 2022 to $19.8B in 2025, while net income margin improved to 29.21%. Analyst consensus is mixed with 38% buy ratings but a $156 price target suggesting modest upside. Recent news highlights strong fee income expectations and a planned 19% dividend increase.
BNY demonstrates solid fundamental strength with improving profitability and consistent earnings beats. The stock offers potential upside to analyst targets and dividend growth, but faces risks from high investing cash outflows and competitive pressures. Current valuation metrics appear reasonable relative to historical performance, though investors should monitor Q2 earnings results for confirmation of growth trajectory.
Tenet Healthcare (THC) trades at $194.81, down 4.62% today, but maintains strong fundamentals with consistent earnings beats and attractive valuation metrics. The stock shows robust profitability with 37.87% ROE and 7.79% net margin, supported by growing outpatient care operations. Technical indicators suggest near-term bearish pressure with key support at $191 and resistance at $198. Recent analyst coverage remains overwhelmingly positive with 81% buy ratings and a $235.88 consensus target.
THC presents a compelling value opportunity with below-market P/E of 9.55 and strong earnings momentum, though technical weakness and upcoming Q2 earnings on July 24 create near-term uncertainty. The expanding ambulatory care segment and defensive healthcare positioning during geopolitical tensions support long-term growth, while debt levels and hospital industry challenges remain key monitoring points.
Trailing returns across standard periods
Latest headlines on both assets
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →